Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences.

Svedsater H, Doll HA, Macey J, Miles G, Bradshaw L, Vanya M.

Adv Ther. 2018 Sep;35(9):1378-1399. doi: 10.1007/s12325-018-0760-7. Epub 2018 Aug 13.

2.

Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study.

Svedsater H, Jones R, Bosanquet N, Jacques L, Lay-Flurrie J, Leather DA, Vestbo J, Collier S, Woodcock A.

Respir Med. 2018 Aug;141:198-206. doi: 10.1016/j.rmed.2018.06.003. Epub 2018 Jun 6.

3.

Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study.

Jacques L, Bakerly ND, New JP, Svedsater H, Lay-Flurrie J, Leather DA.

J Asthma. 2018 Oct 16:1-10. doi: 10.1080/02770903.2018.1490751. [Epub ahead of print]

PMID:
29972089
4.

Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD): follow-up interviews on patient-centred outcomes.

Doward L, Svedsater H, Whalley D, Crawford R, Leather D, Lay-Flurrie J, Bosanquet N.

NPJ Prim Care Respir Med. 2017 Dec 15;27(1):66. doi: 10.1038/s41533-017-0066-2.

5.

Evaluation and quantification of treatment preferences for patients with asthma or COPD using discrete choice experiment surveys.

Svedsater H, Leather D, Robinson T, Doll H, Nafees B, Bradshaw L.

Respir Med. 2017 Nov;132:76-83. doi: 10.1016/j.rmed.2017.09.010. Epub 2017 Sep 27.

6.

Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication.

Chapman S, Dale P, Svedsater H, Stynes G, Vyas N, Price D, Horne R.

NPJ Prim Care Respir Med. 2017 Nov 14;27(1):61. doi: 10.1038/s41533-017-0061-7.

7.

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.

Woodcock A, Vestbo J, Bakerly ND, New J, Gibson JM, McCorkindale S, Jones R, Collier S, Lay-Flurrie J, Frith L, Jacques L, Fletcher JL, Harvey C, Svedsater H, Leather D; Salford Lung Study Investigators.

Lancet. 2017 Nov 18;390(10109):2247-2255. doi: 10.1016/S0140-6736(17)32397-8. Epub 2017 Sep 10. Erratum in: Lancet. 2017 Nov 18;390(10109):e40. Lancet. 2018 Feb 3;391(10119):430.

PMID:
28903864
8.

Life Impact and Treatment Preferences of Individuals with Asthma and Chronic Obstructive Pulmonary Disease: Results from Qualitative Interviews and Focus Groups.

Svedsater H, Roberts J, Patel C, Macey J, Hilton E, Bradshaw L.

Adv Ther. 2017 Jun;34(6):1466-1481. doi: 10.1007/s12325-017-0557-0. Epub 2017 May 23.

9.

A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices.

van der Palen J, Thomas M, Chrystyn H, Sharma RK, van der Valk PD, Goosens M, Wilkinson T, Stonham C, Chauhan AJ, Imber V, Zhu CQ, Svedsater H, Barnes NC.

NPJ Prim Care Respir Med. 2017 Mar 23;27:17001. doi: 10.1038/npjpcrm.2017.1. No abstract available.

10.

Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma-mixed treatment comparisons of clinical efficacy.

Svedsater H, Stynes G, Wex J, Frith L, Leather D, Castelnuovo E, Detry M, Berry S.

Asthma Res Pract. 2016 Feb 8;2:4. doi: 10.1186/s40733-015-0016-0. eCollection 2016.

11.

A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices.

van der Palen J, Thomas M, Chrystyn H, Sharma RK, van der Valk PD, Goosens M, Wilkinson T, Stonham C, Chauhan AJ, Imber V, Zhu CQ, Svedsater H, Barnes NC.

NPJ Prim Care Respir Med. 2016 Nov 24;26:16079. doi: 10.1038/npjpcrm.2016.79.

12.

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindale S, Collier S, Crawford J, Frith L, Harvey C, Svedsater H, Woodcock A; Salford Lung Study Investigators.

N Engl J Med. 2016 Sep 29;375(13):1253-60. doi: 10.1056/NEJMoa1608033. Epub 2016 Sep 4.

13.

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.

Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S.

Respir Res. 2015 Feb 15;16:25. doi: 10.1186/s12931-015-0184-8. Review.

14.

Measurement properties of an asthma symptom and rescue medication use diary.

Clark M, Martin S, Svedsater H, Dale P, Jacques L.

J Asthma. 2015 Feb;52(1):88-97. doi: 10.3109/02770903.2014.947430. Epub 2014 Sep 10.

PMID:
25207984
15.

Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma.

Svedsater H, Jacques L, Goldfrad C, Bleecker ER.

NPJ Prim Care Respir Med. 2014 Jun 26;24:14019. doi: 10.1038/npjpcrm.2014.19. No abstract available.

16.

Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder.

Montgomery SA, Locklear JC, Svedsäter H, Eriksson H.

Int Clin Psychopharmacol. 2014 Sep;29(5):252-62. doi: 10.1097/YIC.0000000000000026.

PMID:
24394383
17.

Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.

Svedsater H, Dale P, Garrill K, Walker R, Woepse MW.

BMC Pulm Med. 2013 Dec 7;13:72. doi: 10.1186/1471-2466-13-72.

18.

Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study.

Sheehan DV, Svedsäter H, Locklear JC, Eriksson H.

J Affect Disord. 2013 Dec;151(3):906-13. doi: 10.1016/j.jad.2013.07.037. Epub 2013 Aug 16.

PMID:
24135509
19.

Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate.

Clayton AH, Locklear JC, Svedsäter H, McIntyre RS.

CNS Spectr. 2014 Apr;19(2):182-96. doi: 10.1017/S1092852913000631. Epub 2013 Sep 25.

PMID:
24067192
20.

Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder.

Locklear JC, Svedsäter H, Datto C, Endicott J.

J Affect Disord. 2013 Jul;149(1-3):189-95. doi: 10.1016/j.jad.2013.01.021. Epub 2013 Apr 29.

PMID:
23639212
21.

Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy.

Thase ME, Montgomery S, Papakostas GI, Bauer M, Trivedi MH, Svedsäter H, Locklear JC, Gustafsson U, Datto C, Eriksson H.

Int Clin Psychopharmacol. 2013 May;28(3):113-20. doi: 10.1097/YIC.0b013e32835fb971.

PMID:
23485955
22.

Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate.

Sheehan DV, Locklear J, Svedsäter H, Datto C.

Int Clin Psychopharmacol. 2012 Sep;27(5):239-48. doi: 10.1097/YIC.0b013e328356ac78.

PMID:
22859063
23.

Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder.

Endicott J, Svedsäter H, Locklear JC.

Neuropsychiatr Dis Treat. 2012;8:301-11. doi: 10.2147/NDT.S32320. Epub 2012 Jul 11.

24.

Humanistic and economic burden of generalized anxiety disorder in North America and Europe.

Revicki DA, Travers K, Wyrwich KW, Svedsäter H, Locklear J, Mattera MS, Sheehan DV, Montgomery S.

J Affect Disord. 2012 Oct;140(2):103-12. doi: 10.1016/j.jad.2011.11.014. Epub 2011 Dec 9. Review.

PMID:
22154706
25.

Assessment of quality of life enjoyment and satisfaction questionnaire-short form responder thresholds in generalized anxiety disorder and bipolar disorder studies.

Wyrwich KW, Harnam N, Revicki DA, Locklear JC, Svedsater H, Endicott J.

Int Clin Psychopharmacol. 2011 May;26(3):121-9. doi: 10.1097/YIC.0b013e3283427cd7. Review.

PMID:
21164351
26.

Understanding the relationships between health outcomes in generalized anxiety disorder clinical trials.

Wyrwich KW, Harnam N, Locklear JC, Svedsäter H, Revicki DA.

Qual Life Res. 2011 Mar;20(2):255-62. doi: 10.1007/s11136-010-9734-1. Epub 2010 Aug 31.

PMID:
20809194
27.

Assessing health-related quality of life in generalized anxiety disorder using the Quality Of Life Enjoyment and Satisfaction Questionnaire.

Wyrwich K, Harnam N, Revicki DA, Locklear JC, Svedsäter H, Endicott J.

Int Clin Psychopharmacol. 2009 Nov;24(6):289-95. doi: 10.1097/YIC.0b013e32832d6bf4.

PMID:
19707153
28.

Covariation neglect among novice investors.

Hedesström TM, Svedsäter H, Gärling T.

J Exp Psychol Appl. 2006 Sep;12(3):155-65.

PMID:
16953742

Supplemental Content

Loading ...
Support Center